治疗复杂性皮肤软组织感染的当前与未来选择:聚焦氟喹诺酮类与长效脂糖肽类抗生素
细菌性皮肤软组织感染常见且负担重,因病原体多样、部分耐药、临床表现广谱及进展为危及生命形式的风险而诊治复杂。需要更高效的诊疗路径以减少住院和住院时间,同时保持高质量医疗并遵循抗菌药物管理原则。本文讨论第四代氟喹诺酮类德拉沙星及长效脂糖肽类达巴万星和奥利万星的临床与药理学特征。
要点
- 细菌性皮肤软组织感染疾病负担重,病原体多样且部分耐药,需高效诊疗路径。
- 近期获批的急性细菌性皮肤及皮肤结构感染治疗药物具有满足减少住院需求的特性。
- 本文聚焦德拉沙星、达巴万星和奥利万星的临床与药理学特征。
核心结论
- 近期获批的急性细菌性皮肤及皮肤结构感染治疗药物具有可减少住院和住院时间并遵循抗菌药物管理原则的特性。
研究设计与样本
- 综述,讨论第四代氟喹诺酮类德拉沙星及长效脂糖肽类达巴万星和奥利万星的临床与药理学特征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bacterial skin and soft tissue infections are among the most common bacterial infections and constitute a major burden for patients and healthcare systems. Care is complicated by the variety of potential pathogens, some with resistance to previously effective antimicrobial agents, the wide spectrum of clinical presentations and the risk of progression to life-threatening forms. More-efficient care pathways are needed that can reduce hospital admissions and length of stay, while maintaining a high quality of care and adhering to antimicrobial stewardship principles. Several agents approved recently for treating acute bacterial skin and skin structure infections have characteristics that meet these requirements. We address the clinical and pharmacological characteristics of the fourth-generation fluoroquinolone delafloxacin, and the long-acting lipoglycopeptide agents dalbavancin and oritavancin.
引用
- Eckmann C, Tulkens PM. Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics. J Antimicrob Chemother. 2021. PMID: 34849999. doi:10.1093/jac/dkab351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。